AAOS Now, August 2013
Will YODA End Debate Over rhBMP-2?
The word is in from the Yale Open Data Access (YODA) project: recombinant human bone morphogenetic protein (rhBMP-2), the product marketed as Infuse® by Medtronic, Inc., offers no appreciable benefit over autograft in spinal fusion surgery. The judgment is the result of an unprecedented move by the manufacturer, which turned over all patient data to the YODA project for review.
Sunshine Act Data Collection Begins
As of August 1, medical drug and device manufacturers and group purchasing organizations (GPOs) began collecting data on payments and transfers of value (TOV) made to U.S. healthcare providers. The data collection is required under the Physician Payment Sunshine Act (Sunshine Act), which establishes a publicly accessible database disclosing potential conflicts of interest between physicians and applicable medical drug and device manufacturers. The data collected between Aug. 1 and Dec.